Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus intravenous pulse steroids versus intravenous pulse steroids alone for acute anterior ischemic optic neuropathy in giant cell arteritis
2019-001145-40Phase 2Active
- Sponsor
- Quinze-Vingts Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in giant cell arteritis (GCA) (2 arms), sponsored by Quinze-Vingts Hospital. Started Nov 2019; status: active.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2019-001145-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001145-40.